Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1999-3-23
pubmed:abstractText
In the present study the possible influence of the antacid Maalox on the pharmacokinetics of capecitabine (Xeloda) and its metabolites was investigated in cancer patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0344-5704
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
309-15
pubmed:dateRevised
2009-11-2
pubmed:meshHeading
pubmed-meshheading:10071982-Administration, Oral, pubmed-meshheading:10071982-Adult, pubmed-meshheading:10071982-Aged, pubmed-meshheading:10071982-Aluminum Hydroxide, pubmed-meshheading:10071982-Antacids, pubmed-meshheading:10071982-Antineoplastic Agents, pubmed-meshheading:10071982-Biotransformation, pubmed-meshheading:10071982-Cross-Over Studies, pubmed-meshheading:10071982-Deoxycytidine, pubmed-meshheading:10071982-Drug Combinations, pubmed-meshheading:10071982-Female, pubmed-meshheading:10071982-Fluorouracil, pubmed-meshheading:10071982-Half-Life, pubmed-meshheading:10071982-Humans, pubmed-meshheading:10071982-Magnesium Hydroxide, pubmed-meshheading:10071982-Male, pubmed-meshheading:10071982-Metabolic Clearance Rate, pubmed-meshheading:10071982-Middle Aged, pubmed-meshheading:10071982-Neoplasms
pubmed:year
1999
pubmed:articleTitle
Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients.
pubmed:affiliation
Department of Pharma Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial